Core Services

Enhanced Services



The FDA approved the use of Buprenorphine, in the form of SUBOXONE and Subutex, to treat opiate dependence on October 8, 2002 for medical maintenance and medically supervised withdrawal. Buprenorphine is a partial agonist that is available for use solely by certified physicians in addiction medicine and those who have satisfied qualifications set-forth by and under the Drug Addiction Treatment Act of 2000 (DATA 2000).

SUBOXONE is used in to manage addiction to opiates including heroin, oxycodone, hydrocodone, morphine and fentanyl. SUBOXONE at the appropriate dose may be used to reduce illicit opioid use and help patients stay in treatment by suppressing symptoms of opioid withdrawal and decreasing cravings for opioids. SUBOXONE treatment can be broken down into 5 phases: Intake, Induction, Stabilization, Maintenance and Medically Supervised Withdrawal.

Methadone is used for both detoxification and maintenance treatment. Detoxification from opiates is the treatment classification for any person who receives gradual decreasing dosages of methadone over a period of 180 days or less. Methadone maintenance is the treatment classification for all clients who receive a regular dose of methadone for a period lasting more than 180 days. Under this classification, gradual increasing dosages of methadone are administered until clients reach a stabilized or blocking dosage.

At this point the person does not feel the effects of any opiates that might be taken. Also, the appearance of the person is almost indistinguishable from that of the nonsubstance abuser. Persons admitted to this unit must be at least 18 years old, show evidence of opiate dependence for at least one year, and voluntarily participate in treatment. Persons under 18 years old must have parental consent. Pregnant women, regardless of age, who have a documented dependency, will be admitted.